Topical cyclosporine can handle more than dry-eye disease

June 15, 2004

Article

Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Subscribe Now!

Recent Videos

Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.

Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.

Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford

About Us

Editorial

Terms and Conditions

Do Not Sell My Information

Privacy

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Topical cyclosporine can handle more than dry-eye disease

Newsletter